A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
Pfizer
Qilu Pharmaceutical Co., Ltd.
Genentech, Inc.
Tyligand Pharmaceuticals (Suzhou) Limited
M.D. Anderson Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.